SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance

03 Mar, 2026

Authors: Grasa C, Salvadori N, Nardone A, Than-in-at K, Koblansky A, Parry C, Thakkar N, Wang M, Giaquinto C, Rojo P & Cressey RT

Published in: BMC Infectious Diseases